Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,780.80
(
-0.06%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.43
(
-2.02%
)
Bitcoin
70,129.35
(
-1.56%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

pharmaclown35

Send PM Follow Ignore
Followers 1
Posts 202
Boards Moderated 0
Alias Born 01/23/2008

pharmaclown35

Re: DewDiligence post# 130880

Monday, 11/28/2011 9:28:41 PM

Monday, November 28, 2011 9:28:41 PM

Post# of 257262
Yup. I agree. Who would have thought BG-12 stood a chance. But do you think the once-daily vs BID for BG-12 will make some MS patients less compliant in the real-world setting?

Also, ACOR -- - what / where can the company go from here. That's what I want to see. I keep waiting for them to in-lisence something good to add to their pipeline.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now